Emcure Pharmaceuticals Ltd

SBI Life Insurance Company Ltd, Info Edge (India) Ltd, Can Fin Homes Ltd, HEG Advanced Materials Ltd are among the other stocks to see a surge in volumes on BSE today, 04 November 2026.Emcure Pharmaceuticals Ltd clocked volume of 1.27 lakh shares by 10:48 IST on BSE, a 9.77 times surge over two-week average daily volume of 13045 shares. The stock gained 9.08% to Rs.2,162.50. Volumes stood at 35222 shares in the last session.SBI Life Insurance Company Ltd recorded volume of 7.52 lakh shares by 10:48 IST on BSE, a 8.71 times surge over two-week average daily volume of 86361 shares. The stock gained 0.26% to Rs.1,690.00. Volumes stood at 37017 shares in the last session.Info Edge (India) Ltd witnessed volume of 5.04 lakh shares by 10:48 IST on BSE, a 6.53 times surge over two-week average daily volume of 77274 shares. The stock dropped 0.65% to Rs.1,170.40. Volumes stood at 2.42 lakh shares in the last session.Can Fin Homes Ltd saw volume of 3.02 lakh shares by 10:48 IST on BSE, a 4.67 fold spurt over two-week average daily volume of 64671 shares. The stock dropped 0.41% to Rs.733.20. Volumes stood at 5.06 lakh shares in the last session.HEG Advanced Materials Ltd clocked volume of 4.77 lakh shares by 10:48 IST on BSE, a 4.53 times surge over two-week average daily volume of 1.05 lakh shares. The stock gained 7.79% to Rs.259.50. Volumes stood at 1.3 lakh shares in the last session.

Emcure Pharmaceuticals Ltd share price rose by 5.31% to Rs 1982.55 after the company's net profit improved by 11.14% to Rs 325.07 crore, while revenue from operations slightly gained 9.30% to Rs 2820.47 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, gaining 5.41%. It has marginally improved by 1.84% over last one week and ticked higher by 1.37% in last one month while the market capitalization of Emcure Pharmaceuticals Ltd has inched up 5.83% and 2.42% in the same period respectively. Profit before tax (PBT) of Emcure Pharmaceuticals Ltd stood at Rs 445.85 crore in Q3 FY26, rallying 30.59% year-on-year, and improving 13.30% quarter-on-quarter. EBITDA came in at Rs 585 crore, surging by 23.76% YoY and advancing by 10.21% sequentially. Total expenses grew marginally by 8.57% to Rs 2342.3 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 642.13 crore, soaring by 33.46% YoY, while employee benefits expense was at Rs 434.71 crore, ticking higher by 6.16% YoY. For the TTM ended FY26, revenue from operations rose 16.56% to Rs 9203.54 crore, while net profit surged by 33.05% to Rs 941.27 crore, compared to previous TTM. EBITDA soared by 143704% to Rs 1851.89 crore, and PBT jumped 32.51% to Rs 1287.14 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 943.55 crore in FY26, as against Rs 851.71 crore in FY25. Emcure Pharmaceuticals Ltd rallied 49.58% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 8.41% during the same period.

Emcure Pharmaceuticals Ltd share price inched up 0.77% to Rs 1882.5 after the company's net profit rose by 11.14% to Rs 325.07 crore, while revenue from operations improved marginally 9.30% to Rs 2820.47 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 5.09%. It has marginally improved by 2.16% over last one week and moved up slightly by 0.86% in last one month while the market capitalization of Emcure Pharmaceuticals Ltd has inched up 0.39% and 3.89% in the same period respectively. Profit before tax (PBT) of Emcure Pharmaceuticals Ltd stood at Rs 445.85 crore in Q3 FY26, expanding by 30.59% year-on-year, and heading higher 13.30% quarter-on-quarter. EBITDA came in at Rs 585 crore, rallying 23.76% YoY and advancing by 10.21% sequentially. Total expenses saw a slight increase of 8.57% to Rs 2342.3 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 642.13 crore, witnessing a sharp rise of 33.46% YoY, while employee benefits expense was at Rs 434.71 crore, inching up 6.16% YoY. For the TTM ended FY26, revenue from operations rose 16.56% to Rs 9203.54 crore, while net profit soared by 33.05% to Rs 941.27 crore, compared to previous TTM. EBITDA jumped by 143704% to Rs 1851.89 crore, and PBT jumped 32.51% to Rs 1287.14 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 943.55 crore in FY26, as against Rs 851.71 crore in FY25. Emcure Pharmaceuticals Ltd rallied 42.03% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 9.87% during the same period.

Emcure Pharmaceuticals Limited will hold a board meeting on November 3, 2026, to approve the unaudited financial results for both standalone and consolidated entities for the quarter and half-year ended September 30, 2026, according to a regulatory filing with the National Stock Exchange of India and BSE Limited. The trading window for company insiders has been closed since October 1, 2026, and will remain closed until November 5, 2026.

Emcure Pharmaceuticals Limited confirmed receipt of a certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, regarding dematerialization of securities for the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Emcure Pharmaceuticals Limited announced that its board approved a draft composite scheme of amalgamation involving Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, both wholly owned subsidiaries, with Emcure Pharmaceuticals Limited. The amalgamation is intended to achieve entity rationalization and operational efficiency within the group and is subject to statutory and regulatory approvals, including the National Company Law Tribunal, Mumbai Bench. As of March 31, 2026, Zuventus Healthcare Limited had a net worth of Rs 871.46 crore and turnover of Rs 1,040.58 crore, while Emcutix Biopharmaceuticals Limited had a net worth of negative Rs 13.07 crore and turnover of Rs 29.37 crore, and Emcure Pharmaceuticals Limited had a net worth of Rs 3,710.60 crore and turnover of Rs 5,243.19 crore.

Emcure Pharmaceuticals Limited has disclosed receiving penalty orders totaling Rs 57,73,96,732 from the Income-tax Department related to financial years 2014-15 through 2020-21 (assessment years 2015-16 to 2021-22), as revealed in documents submitted to the National Stock Exchange of India Limited and BSE Limited on October 2, 2026. The company is currently evaluating legal options, including filing an appeal before the Appellate Authority, in response to these orders which stem from ongoing litigations previously disclosed in governance reports up to the quarter ended June 30, 2026.

Emcure Pharmaceuticals Limited will close its trading window for designated persons and their immediate relatives starting Thursday, October 1, 2026, and continuing for 48 hours after the declaration of the unaudited financial results for the quarter and half year ending September 30, 2026, as per Securities and Exchange Board of India regulations.

Emcure Pharmaceuticals Limited announced that its Nomination and Remuneration Committee approved the allotment of 11,400 equity shares to eligible employees under the Emcure - Employee Stock Option Scheme 2013, following the exercise of 11,400 vested options. The allotment increases the company’s issued and paid-up share capital from 18,96,99,247 equity shares to 18,97,10,647 equity shares, with an aggregate value increasing from Rs 1,89,69,92,470 to Rs 1,89,71,06,470.

Emcure Pharmaceuticals Ltd. announced reaffirmations from CARE Ratings Limited and CARE Ratings Ltd. regarding several instruments, including Long-term bank facilities totaling Rs 785.00, Long-term/Short-term bank facilities amounting to Rs 1,563.00, and Short-term bank facilities of Rs 52.00, all carrying ratings of CARE AA; Stable and CARE A1+ respectively, with enhancements to the amounts from Rs 557.50 and Rs 1,348.00 previously; additionally, CARE Ratings Limited (CareEdge Ratings) noted potential for a positive rating upgrade if total operating income and PBILDT margins exceed 22%, while a downgrade could occur if net debt to PBILDT rises above 1.50x or PBILDT margins fall below 15%, alongside the withdrawal of ratings for Non-convertible debentures LT as of January 5, 2024, and the completion of the acquisition of a stake in Gennova Biopharmaceuticals Limited for approximately Rs 232 crore in July 2026, alongside a divestment of its mRNA business for roughly Rs 140 crore.